• Medientyp: E-Book
  • Titel: The Carbonic Anhydrases: Current and Emerging Therapeutic Targets
  • Beteiligte: Chegwidden, W. Richard [HerausgeberIn]; Carter, Nicholas D. [HerausgeberIn]
  • Erschienen: Cham: Springer International Publishing, 2021.
    Cham: Imprint: Springer, 2021.
  • Erschienen in: Progress in Drug Research ; 75
    Springer eBook Collection
  • Ausgabe: 1st ed. 2021.
  • Umfang: 1 Online-Ressource(XII, 288 p. 38 illus., 22 illus. in color.)
  • Sprache: Englisch
  • DOI: 10.1007/978-3-030-79511-5
  • ISBN: 9783030795115
  • Identifikator:
  • RVK-Notation: WD 5070 : Lyasen, Synthasen
    VX 8500 : Allgemeines
  • Schlagwörter: Carboanhydrase > Zielstruktur > Pharmakotherapie
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: Dedication -- Preface.-The carbonic anhydrases in health and disease -- Carbonic anhydrase isozymes as diagnostic biomarkers and therapeutic targets -- Targeting carbonic anhydrases in vascular and pulmonary disease -- Carbonic anhydrase inhibitors in ophthalmology: glaucoma and macular oedema -- Targeting carbonic anhydrase isozymes in the treatment of neurological disorders -- Potential of carbonic anhydrase inhibitors in the treatment of oxidative stress and diabetes -- An overview of carbonic anhydrase-related neoplasms -- The carbonic anhydrase IX interactome and the regulation of cancer progression -- Carbonic anhydrase IX: current and emerging therapies -- Carbonic anhydrase inhibitors: designing isozyme-specific inhibitors as therapeutic agents -- Carbonic anhydrase inhibitors: identifying therapeutic cancer agents through virtual screening -- Targeting carbonic anhydrase IX in tumour imaging and theranostic cancer therapy.

    This volume assembles and integrates the wealth of diverse information that is now accumulating in this burgeoning field. The existing and potential therapeutic applications of targeting CA cover a remarkably wide-range of diseases and disorders and have generated increasing and extensive interest in recent years. Its inter-disciplinary approach embraces both the most up-to-date therapeutic application of CA-targeting and the latest research data that will provide a platform for the development of novel applications. The interested audience comprises scientists and clinicians from many relevant disciplines within science and medicine.